Evidence map›Paper›PMID 34572879›Full record

ArticleCancers2021

Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer.

Katherine B Sahin, Esha T Shah, Genevieve P Ferguson, Christopher Molloy, Priyakshi Kalita-de Croft, Sarah A Hayes, Amanda Hudson, Emily Colvin, Hannah Kamitakahara, Rozelle Harvie and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Pan-cancer analysis identifiesTranslational cancer research · 2022
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 2 countries.

Katherine B SahinCentre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4059, Australia.
Esha T ShahCentre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4059, Australia.ORCID 0000-0002-7626-1085
Genevieve P FergusonCentre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4059, Australia.
Christopher MolloyCentre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4059, Australia.
Priyakshi Kalita-de CroftUQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Herston, QLD 4006, Australia.ORCID 0000-0001-8877-7655
Sarah A HayesBill Walsh Translational Research Laboratory, Faculty of Medicine and Health, Kolling Institute, University of Sydney, Royal North Shore Hospital, Reserve Road, St Leonards, NSW 2065, Australia.
Amanda HudsonBill Walsh Translational Research Laboratory, Faculty of Medicine and Health, Kolling Institute, University of Sydney, Royal North Shore Hospital, Reserve Road, St Leonards, NSW 2065, Australia.
Emily ColvinBill Walsh Translational Research Laboratory, Faculty of Medicine and Health, Kolling Institute, University of Sydney, Royal North Shore Hospital, Reserve Road, St Leonards, NSW 2065, Australia.
Hannah KamitakaharaBill Walsh Translational Research Laboratory, Faculty of Medicine and Health, Kolling Institute, University of Sydney, Royal North Shore Hospital, Reserve Road, St Leonards, NSW 2065, Australia.ORCID 0000-0003-2011-0584
Rozelle HarvieBill Walsh Translational Research Laboratory, Faculty of Medicine and Health, Kolling Institute, University of Sydney, Royal North Shore Hospital, Reserve Road, St Leonards, NSW 2065, Australia.
Csilla HasovitsBill Walsh Translational Research Laboratory, Faculty of Medicine and Health, Kolling Institute, University of Sydney, Royal North Shore Hospital, Reserve Road, St Leonards, NSW 2065, Australia.
Tashbib KhanMater Research Institute, Translational Research Institute, The University of Queensland, Woolloongabba, QLD 4102, Australia.ORCID 0000-0001-5203-0672
Pascal H G DuijfCentre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4059, Australia.ORCID 0000-0001-8646-9843
Viive M HowellBill Walsh Translational Research Laboratory, Faculty of Medicine and Health, Kolling Institute, University of Sydney, Royal North Shore Hospital, Reserve Road, St Leonards, NSW 2065, Australia.ORCID 0000-0002-2356-3231
Yaowu HeMater Research Institute, Translational Research Institute, The University of Queensland, Woolloongabba, QLD 4102, Australia.ORCID 0000-0002-7828-263X
Emma BoldersonCentre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4059, Australia.
John D HooperMater Research Institute, Translational Research Institute, The University of Queensland, Woolloongabba, QLD 4102, Australia.ORCID 0000-0003-1054-8486
Sunil R LakhaniUQ Centre for Clinical Research, Faculty of Medicine, University of Queensland, Herston, QLD 4006, Australia.ORCID 0000-0003-4067-2760
Derek J RichardCentre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4059, Australia.
Kenneth J O'ByrneCentre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4059, Australia.
Mark N AdamsCentre for Genomics and Personalised Health, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4059, Australia.ORCID 0000-0003-1906-5018
Queensland University of Technology · AUThe University of Sydney · AUTranslational Research Institute · AUThe University of Queensland · AUOslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tyrosine kinase inhibitors (TKIs) are the first-line therapy for non-small-cell lung cancers (NSCLC) that harbour sensitising mutations within the epidermal growth factor receptor (EGFR). However, resistance remains a key issue, with tumour relapse likely to occur. We have previously identified that cell division cycle-associated protein 3 (CDCA3) is elevated in adenocarcinoma (LUAD) and correlates with sensitivity to platinum-based chemotherapy. Herein, we explored whether CDCA3 levels were associated with EGFR mutant LUAD and TKI response. We demonstrate that in a small-cohort tissue microarray and in vitro LUAD cell line panel, CDCA3 protein levels are elevated in EGFR mutant NSCLC as a result of increased protein stability downstream of receptor tyrosine kinase signalling. Here, CDCA3 protein levels correlated with TKI potency, whereby CDCA3

Indexed as

acquired resistancebiomarkercell division cycle-associated protein 3 (CDCA3)epidermal growth factor receptor (EGFR)non-small-cell lung cancer (NSCLC)tyrosine kinase inhibitor (TKI)

Identifiers

PMID34572879
PMCPMC8466783
OpenAlexW3200770057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.